394 related articles for article (PubMed ID: 9544670)
1. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy.
Lastoria S; Vergara E; Palmieri G; Acampa W; Varrella P; Caracò C; Bianco RA; Muto P; Salvatore M
J Nucl Med; 1998 Apr; 39(4):634-9. PubMed ID: 9544670
[TBL] [Abstract][Full Text] [Related]
2. Current role of 111In-DTPA-octreotide scintigraphy in diagnosis of thymic masses.
Guidoccio F; Grosso M; Maccauro M; Orsini F; Perri M; Boni G; Banti E; Grassetto G; Rubello D; Mariani G; Volterrani D
Tumori; 2011; 97(2):191-5. PubMed ID: 21617714
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor scintigraphy in thymoma imaging method and clinical application.
Marienhagen J; Schalke B; Aebert H; Held P; Eilles C; Bogdahn U
Pathol Res Pract; 1999; 195(8):575-81. PubMed ID: 10483589
[TBL] [Abstract][Full Text] [Related]
4. Functional imaging of thymic disorders.
Lastoria S; Palmieri G; Muto P; Lombardi G
Ann Med; 1999 Oct; 31 Suppl 2():63-9. PubMed ID: 10574158
[TBL] [Abstract][Full Text] [Related]
5. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
[TBL] [Abstract][Full Text] [Related]
6. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
7. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998.
Raderer M; Kurtaran A; Leimer M; Angelberger P; Niederle B; Vierhapper H; Vorbeck F; Hejna MH; Scheithauer W; Pidlich J; Virgolini I
J Clin Oncol; 2000 Mar; 18(6):1331-6. PubMed ID: 10715305
[TBL] [Abstract][Full Text] [Related]
8. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor imaging in intracranial tumours.
Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro.
Ferone D; van Hagen MP; Kwekkeboom DJ; van Koetsveld PM; Mooy DM; Lichtenauer-Kaligis E; Schönbrunn A; Colao A; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2000 Apr; 85(4):1719-26. PubMed ID: 10770220
[TBL] [Abstract][Full Text] [Related]
12. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.
Andersson P; Forssell-Aronsson E; Johanson V; Wängberg B; Nilsson O; Fjälling M; Ahlman H
J Nucl Med; 1996 Dec; 37(12):2002-6. PubMed ID: 8970523
[TBL] [Abstract][Full Text] [Related]
13. [Thoracic SPECT using (111 In-DTPA-D-Phe1)-octreotide in bronchial carcinoid syndrome].
Banzo J; Sebastián A; Prats E; Freile E; García F; Costán J; Razola P; Tomás A; Cegoñino J; Abós MD
Rev Esp Med Nucl; 1998; 17(1):45-8. PubMed ID: 9609844
[TBL] [Abstract][Full Text] [Related]
14. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
[TBL] [Abstract][Full Text] [Related]
15. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report.
Liu RS; Yeh SH; Huang MH; Wang LS; Chu LS; Chang CP; Chu YK; Wu LC
Eur J Nucl Med; 1995 Dec; 22(12):1402-7. PubMed ID: 8586085
[TBL] [Abstract][Full Text] [Related]
16. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
[TBL] [Abstract][Full Text] [Related]
17. Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors.
De Luca S; Fonti R; Palmieri G; Federico P; Del Prete G; Pacelli R; Pace L; De Placido S; Salvatore M; Del Vecchio S
Clin Nucl Med; 2013 May; 38(5):354-8. PubMed ID: 23486323
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis.
Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I
J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133
[TBL] [Abstract][Full Text] [Related]
19. The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours.
Fukumoto K; Taniguchi T; Ishikawa Y; Kawaguchi K; Fukui T; Kato K; Matsuo K; Yokoi K
Eur J Cardiothorac Surg; 2012 Dec; 42(6):e152-6. PubMed ID: 23024234
[TBL] [Abstract][Full Text] [Related]
20. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
